{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:29:34Z","timestamp":1759883374475,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.gene.2022.146960","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T19:03:26Z","timestamp":1665255806000},"page":"146960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Very important pharmacogenes polymorphism landscape and potential clinical relevance in the Chinese Mongolian"],"prefix":"10.1016","volume":"850","author":[{"given":"Le","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-6501","authenticated-orcid":false,"given":"Tianbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gene.2022.146960_b0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10903-021-01264-x","article-title":"Variability of CYP2C8 polymorphisms in three jordanian populations: circassians, chechens and jordanian-arabs","volume":"24","author":"Abudahab","year":"2022","journal-title":"J. Immigr. Minor. Health"},{"issue":"5","key":"10.1016\/j.gene.2022.146960_b0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4103\/0971-5916.187106","article-title":"N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures \u2013 a pilot study","volume":"143","author":"Adole","year":"2016","journal-title":"Ind. J. Med. Res."},{"key":"10.1016\/j.gene.2022.146960_b0015","doi-asserted-by":"crossref","first-page":"144408","DOI":"10.1016\/j.gene.2020.144408","article-title":"Pharmacogenomic landscape of VIP genetic variants in Jordanian Arabs and comparison with worldwide populations","volume":"737","author":"AL-Eitan","year":"2020","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0020","doi-asserted-by":"crossref","first-page":"e2194","DOI":"10.1002\/rmv.2194","article-title":"Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment","volume":"31","author":"Al-Eitan","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.gene.2022.146960_b0025","doi-asserted-by":"crossref","unstructured":"Al-Eitan, L.N., Rababa'h, D.M., Hakooz, N.M., Alghamdi, M.A., Dajani, R.B., 2020. Genetic polymorphisms of pharmacogenes among the genetically isolated circassian subpopulation from Jordan. J. Personal. Med. 2020;10(1). doi:10.3390\/jpm10010002.","DOI":"10.3390\/jpm10010002"},{"issue":"8","key":"10.1016\/j.gene.2022.146960_b0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/1389200220666190729124000","article-title":"Genetic polymorphisms of pharmacogenomic VIP variants in the circassian subpopulation from Jordan","volume":"20","author":"Al-Eitan","year":"2019","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.gene.2022.146960_b0035","first-page":"199","article-title":"Analysis of comprehensive pharmacogenomic profiling of VIP variants among the genetically isolated chechen subpopulation from Jordan","volume":"13","author":"Al-Eitan","year":"2020","journal-title":"Pharmacogenomics Pers. Med."},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1389200221666200505081139","article-title":"Genetic analysis of pharmacogenomic VIP variants of ABCB1, VDR and TPMT genes in an ethnically isolated population from the north caucasus living in Jordan","volume":"21","author":"Al-Eitan","year":"2020","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78231-3","article-title":"Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations","volume":"10","author":"Al-Mahayri","year":"2020","journal-title":"Sci. Rep."},{"issue":"9678","key":"10.1016\/j.gene.2022.146960_b0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0055","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: A worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fca.12.31","article-title":"The future of warfarin pharmacogenetics in under-represented minority groups","volume":"8","author":"Cavallari","year":"2012","journal-title":"Fut. Cardiol."},{"key":"10.1016\/j.gene.2022.146960_b0065","article-title":"Sample size calculations in clinical research","author":"Chow","year":"2017","journal-title":"Chapman and Hall\/CRC"},{"key":"10.1016\/j.gene.2022.146960_b0070","doi-asserted-by":"crossref","first-page":"146825","DOI":"10.1016\/j.gene.2022.146825","article-title":"Genetic polymorphisms of pharmacogenomic VIP variants in the Lahu population from Yunnan Province","volume":"844","author":"Dou","year":"2022","journal-title":"Gene"},{"issue":"6 Pt 1","key":"10.1016\/j.gene.2022.146960_b0075","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1164\/ajrccm.157.6.mar-5","article-title":"Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors","volume":"157","author":"Drazen","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.gene.2022.146960_b0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/clc.22031","article-title":"Aspirin resistance: current status and role of tailored therapy","volume":"35","author":"Grinstein","year":"2012","journal-title":"Clin. Cardiol."},{"issue":"8","key":"10.1016\/j.gene.2022.146960_b0085","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/jgh.12194","article-title":"Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India","volume":"28","author":"Gupta","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.gene.2022.146960_b0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/15563650.2015.1049355","article-title":"CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants","volume":"53","author":"Haufroid","year":"2015","journal-title":"Clinical Toxicology."},{"key":"10.1016\/j.gene.2022.146960_b0095","first-page":"251","article-title":"Polymorphic NATs and cancer predisposition","volume":"148","author":"Hirvonen","year":"1999","journal-title":"IARC Sci. Publ."},{"issue":"6","key":"10.1016\/j.gene.2022.146960_b0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mai.2002.129413","article-title":"Effects of montelukast and beclomethasone on airway function and asthma control","volume":"110","author":"Israel","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.gene.2022.146960_b0105","doi-asserted-by":"crossref","first-page":"144050","DOI":"10.1016\/j.gene.2019.144050","article-title":"Pharmacogenes (PGx-genes): Current understanding and future directions","volume":"718","author":"Katara","year":"2019","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0110","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI74692","article-title":"Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene","volume":"125","author":"Knowles","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0115","first-page":"52","article-title":"Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC)","volume":"83","author":"Lee","year":"2008","journal-title":"study."},{"issue":"4","key":"10.1016\/j.gene.2022.146960_b0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.200509-1412OC","article-title":"Influence of leukotriene pathway polymorphisms on response to montelukast in asthma","volume":"173","author":"Lima","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.gene.2022.146960_b0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00008571-199406000-00003","article-title":"Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene","volume":"4","author":"Lin","year":"1994","journal-title":"Pharmacogenetics."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41397-020-0177-y","article-title":"Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China","volume":"21","author":"Liu","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.gene.2022.146960_b0135","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.2147\/OTT.S149197","article-title":"The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis","volume":"10","author":"Lu","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.gene.2022.146960_b0140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-130-6-199903160-00005","article-title":"Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast\/Beclomethasone Study Group","volume":"130","author":"Malmstrom","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cpt.1643","article-title":"PharmVar GeneFocus: CYP2D6","volume":"107","author":"Nofziger","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.gene.2022.146960_b0150","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.ATV.0000030340.80207.C5","article-title":"Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response","volume":"22","author":"Papafili","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9894","key":"10.1016\/j.gene.2022.146960_b0155","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0140-6736(13)60681-9","article-title":"Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study","volume":"382","author":"Perera","year":"2013","journal-title":"Lancet"},{"issue":"7573","key":"10.1016\/j.gene.2022.146960_b0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.gene.2022.146960_b0165","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.gene.2022.146960_b0170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"33","key":"10.1016\/j.gene.2022.146960_b0175","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11239-012-0777-8","article-title":"Association of COX-2 rs20417 with aspirin resistance","volume":"35","author":"Sharma","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03256314","article-title":"Study of NAT2 gene polymorphisms in an Indian population","volume":"13","author":"Singh","year":"2009","journal-title":"Mol. Diagnosis Therapy"},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.gene.2022.146960_b0195","doi-asserted-by":"crossref","unstructured":"Sirachainan, E., Jaruhathai, S., Trachu, N., et al., 2012. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmacogen. Personal. Med. 5, 149\u201353. doi:10.2147\/pgpm.S32160.","DOI":"10.2147\/PGPM.S32160"},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00404-018-4791-8","article-title":"Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy","volume":"298","author":"Sun","year":"2018","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.gene.2022.146960_b0205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2004.11.014","article-title":"Characterization of within-subject responses to fluticasone and montelukast in childhood asthma","volume":"115","author":"Szefler","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.gene.2022.146960_b0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/FPC.0b013e328326e0b1","article-title":"5-lipoxygenase pharmacogenetics in asthma: overlap with CystLTR1 loci","volume":"19","author":"Tantisira","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"11","key":"10.1016\/j.gene.2022.146960_b0215","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A review of the important role of CYP2D6 in pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","article-title":"Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance","volume":"27","author":"Teh","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.gene.2022.146960_b0225","first-page":"1","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff","year":"2019","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.gene.2022.146960_b0230","first-page":"1647","article-title":"Genetic polymorphisms of very important pharmacogene variants in the Blang population from Yunnan Province in China","volume":"14","author":"Wang","year":"2021","journal-title":"Pharmacogen. Pers. Med."},{"key":"10.1016\/j.gene.2022.146960_b0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.gene.2018.01.040","article-title":"Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China","volume":"648","author":"Yan","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.gene.2022.146960_b0240","article-title":"Associations of candidate gene polymorphisms with poor responsiveness to aspirin: a meta-analysis","author":"Yang","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"10.1016\/j.gene.2022.146960_b0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00438-022-01855-9","article-title":"Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research","volume":"297","author":"Yang","year":"2022","journal-title":"Mol. Genet. Genom. : MGG."},{"issue":"2","key":"10.1016\/j.gene.2022.146960_b0250","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cpt.1491","article-title":"The advantages and challenges of diversity in pharmacogenomics: can minority populations bring us closer to implementation?","volume":"106","author":"Zhang","year":"2019","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:00:03Z","timestamp":1759856403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111922007806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":50,"alternative-id":["S0378111922007806"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2022.146960","relation":{},"ISSN":["0378-1119"],"issn-type":[{"type":"print","value":"0378-1119"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Very important pharmacogenes polymorphism landscape and potential clinical relevance in the Chinese Mongolian","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2022.146960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"146960"}}